News

Dana-Farber/Boston Children's named a top pediatric cancer program

U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the top pediatric cancer program in New England and #2 in the nation in its 2020-21 Best Children's Hospitals report.

Population-based registry data identifies novel cancer patterns in families of childhood cancer patients

A collaboration between the Finnish Cancer Registry and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center explored the utility of population-based registry data to screen childhood cancer patients for history of familial cancer. The study opened a new method for identifying high risk families that may reveal possible novel cancer predisposition genes.

Massive study reveals how 'hypermutated' malignant brain tumors with many mutations escape chemotherapy and immunotherapy

The report’s authors include investigators from Dana-Farber, Brigham and Women’s, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, the Broad Institute of MIT and Harvard, and Pitié-Salpêtrière hospitals in Paris, France, among others.

Dana-Farber/Boston Children’s receives $200,000 grant from Hyundai Hope On Wheels to support COVID-19 testing

Dana-Farber/Boston Children’s physicians have implemented crucial testing protocols during this unusual time, with a focus that children with cancer need life-saving treatments even in the setting of a viral pandemic.

The Osteosarcoma Institute to fund clinical trial in recurrent osteosarcoma at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

The clinical trial will investigate the effectiveness of a combination of two oral drugs targeting the DNA damage response pathway.

Hass-Kogan receives funding for new DIPG-specific research project from Defeat DIPG and ChadTough

Daphne Haas-Kogan, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, will receive a research grant totaling $600,000 over three years for “Dependence of DIPGs on DNA polymerase q for DNA repair defines a new therapeutic target.”

Dana-Farber/Boston Children’s faculty named 2020 Top Doctors

Boston magazine has named at least 25 faculty members of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center to its annual "Top Doctors" guide.

Dana-Farber/Boston Children's nation’s #1 pediatric cancer program

U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the nation’s #1 pediatric cancer program in its new 2019-20 Best Children’s Hospitals rankings.

Children with cancer wait an average of 6.5 years longer than adults to access new targeted drugs, finds study at Dana-Farber/Boston Children’s

Researchers call for expanding children’s access to experimental cancer therapies

Team led by Dana-Farber/Boston Children’s Kimberly Stegmaier receives SU2C Sharp Award from Stand Up To Cancer

Stand Up To Cancer (SU2C) announced on May 2 that a team led by Kimberly Stegmaier, MD, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Sarah Tasian, MD, Children's Hospital of Philadelphia, was awarded a two-year grant totaling $250,000. Their SU2C Sharp Award is titled: Precision combinatorial immunotherapeutic targeting of thymic stromal lymphopoietin receptor (TSLPR) signaling in pediatric and young adult CRLF2-rearranged ALL.